During a recent study, it was found that 73% of the individuals involved were able to successfully adhere to a dosing interval of every 16 weeks. Moreover, close to 60% of the participants displayed the capacity to potentially increase the dosing interval to every 20 weeks. This research was conducted jointly in San Francisco and Suzhou, China and involved Innovent Biologics, Inc. (HKEX: 01801).